Our data suggest that in human immunodeficiency virus-1 infection an increased level of activation is associated with a diminished expression of complement regulatory proteins on CD4+ alveolar lymphocytes. This phenomenon might contribute to the depletion of CD4+ lymphocytes and the local immunodeficiency in the pulmonary compartment.
The hallmark of immunodeficiency in human immunodeficiency virus-1 (HIV-1) infection is the loss of CD4+ T-cells. A conclusive explanation for the depletion of CD4+ T-cells has not been found to date. Apart from direct viral cytopathogenicity of at least some syncytium inducing strains, a number of indirect mechanisms, such as apoptosis and antibody-dependent complementmediated cytotoxicity (ACC), have been proposed.
Normal human cells are protected from the lytic action of homologous complement by membrane proteins that regulate activation and deposition of complement proteins. The membrane proteins complement receptor 1 (CR1 or CD35) [1] , membrane co-factor protein (MCP or CD46) [2] and decay accelerating factor (DAF or CD55) [3] induce the dissociation of the C3 convertases, thus preventing further activation of complement. In addition, CD35 and CD46 act as co-factors for C3b cleavage by the serum enzyme factor I [1, 2] . The membrane inhibitor of reactive lysis (MIRL or CD59) [4] and the homologous restriction factor (HRF) are two membrane proteins that prevent the assembly of the membrane attack complex (C5b-9).
Recently we have shown that certain CD4+ lymphoid cell lines lacking the expression of complement regulatory proteins are susceptible to ACC when infected with HIV-1 [5] . The in vivo significance of this finding remains unclear.
Some reports suggest a decrease of the expression of complement regulatory proteins CD35, CD46, CD55 and CD59 [6] [7] [8] on peripheral blood cells from HIV-1 infected individuals. However, to date no comprehensive evaluation of the expression of complement receptors and regulatory proteins on tissue CD4+ T-cells has been performed. In HIV-1 infected patients, the lung is one of the most frequently affected organs. Infectious pulmonary complications contribute considerably to morbidity and mortality of acquired immune deficiency syndrome (AIDS) patients. It has been postulated that the local immunodeficiency in the lung is due to a progressive decline of the pulmonary cytolytic capacity that is at least partly attributable to a depletion of CD4+ alveolar lymphocytes (ALs) [9] .
The aim of this study was, therefore, to elucidate whether CD4+ ALs from HIV-1 infected individuals have lost protection by complement regulatory proteins, since this increases the susceptility to ACC. As little is known about the regulation of the expression of complement regulatory and receptor proteins on T-cells, we examined the correlation between antigen expression, activation level as assessed by leucocyte functional associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) expression, cytokine production of alveolar cells (ACs) and CD30 status. CD30 is expressed on T-cells that produce predominantly type 2 Thelper (Th2) cytokines (i.e. interleukin (IL)-4, IL-10) rather than type 1 T-helper (Th1) cytokines (i.e. IL-2, interferon gamma (IFN-γ)) [10] .
Patients and methods

Patients
We investigated the expression of complement regulatory proteins and complement receptors on CD4+ ALs and alveolar macrophages (AMs) obtained from 17 HIV-1 infected individuals (mean±SEM age 43±11 yrs; three female and 14 male; six smokers and 11 nonsmokers; one patient stage CDC I, three patients stage II and 13 patients stage III). The mean blood CD4 cell count was 134±133 cells·µL -1 . All but two patients were on current antiretroviral therapy. For comparison, seven healthy volunteers (mean age 25±3 yrs; all male; all nonsmokers) and five patients with suspected (n=2) or proven (n=3; all stage T1, squamous cell carcinomas) peripheral malignancy of the lung (mean age 58±7 yrs; all male; all smokers) were evaluated in the same manner by bronchoalveolar lavage (BAL). In HIV-1 infected patients, BAL was performed for exclusion (10 cases) or confirmation of opportunistic infections (seven patients; Mycobacterium tuberculosis (one), Cryptococcus neoformans (one), Pneumocystis carinii (two), other bacterial infections (three)).
Bronchoalveolar lavage
BAL was performed with a fibrescope (B71T20D; Olympus, Hamburg, Germany) placed in a wedge position in the middle lobe. Six to eight 20 mL aliquots of sterile saline were instilled and immediately aspirated.
Differential cell counts were performed after two washes in sterile saline solution and staining with WrightGiemsa. BAL samples with more than 10% neutrophils were excluded.
Flow cytometry (FACS)
Four million cells were pre-incubated for 30 min with 20% bovine serum (Sigma, Deisenhofen, Germany) to block nonspecific binding. After centrifugation for 10 min at 400×g, cells were washed twice in phosphate buffered saline (PBS) solution. Cells were conveyed in suitably sized FACS tubes and 10 µL antibody was added. After 30 min incubation and two washes with PBS, twocolour flow cytometry (FACScan, Becton-Dickinson, Heidelberg, Germany) was performed using the following monoclonal antibodies: 1) Fluorescein conjugated: anti-CD4 (RPA-T4; Dianova, Hamburg, Germany); 2) R-phycoerythrin conjugated: anti-LFA-1 (C174/38; Biotrend, Köln, Germany), anti-CR3 (C135/44; Biotrend), anti-CR4 (3.9; Sigma, Deisenhofen, Germany), anti-CR2 (MON-1112R; CellSystem, Remagen, Germany), anti-CD30 (Ber-H2; Dako, Hamburg, Germany) and anti-ICAM-1 (C169/15.2; Biotrend); 3) Stained by secondary anti-mouse IgG R-phycoerythrin conjugated (27138, Dianova): anti-CR1 (J3D3; Dianova) and anti-CD46 (J4.48; Immunotech, Hamburg, Germany); and 4) Stained by secondary anti-mouse IgM R-phycoerythrin conjugated (SAM-2F; CellSystem): anti-CD55 (MON-1155; CellSystem) and anti-CD59 (MON-1156; CellSystem).
Fluorescein and R-phycoerythrin conjugated monoclonal antibodies anti-IGG1 (Dianova) were used for negative controls.
In samples with secondary antibodies, anti-CD4 was added after two additional washing procedures; otherwise fluorescein and R-phycoerythrin conjugated antibodies were incubated together.
Instruments were calibrated with beads (Calibrite; Becton-Dickinson) and software (Autocomp; BectonDickinson). For gating and calculation, Lysis II software (Becton-Dickinson) was used. Gating for lymphocytes using forward/sideward scatter was facilitated by CD45/ CD14 (Becton-Dickinson) staining. A minimum of 10,000 events was acquired with at least 50 CD4+ events in the lymphocyte gate, even in severely CD4-cell depleted patients. Log fluorescence intensity was displayed on a histogram in arbitrary fluorescence units. For the quantification of surface markers, linear median intensity emitted by bound monoclonal antibodies was divided by linear fluorescence median intensity of the corresponding isotype control. This calculation corrects for variation in cell autofluorescence between patients. The resulting ratio indicates the fold increase in average antigen density (relative linear mean fluorescence intensity (RLMFI)). A ratio of ≤1 indicates no specific antigen expression.
Cytokines
For evaluation of cytokine secretion, AC concentration was adjusted to 10 6 ACs·mL -1 and cells were cultured unseparated in medium (M199; GIBCO, Eggenstein, Germany) supplemented with 5% foetal calf serum (PAA; Linz, Austria) at 37°C in a 5% CO 2 enriched humidified atmosphere for 24 h. Using commercially available enzyme-linked immunosorbent assay (ELISA) kits, IL-1β (PerSeptive Diagnostics, Cambridge, USA), tumour necrosis factor alpha (TNF-α) (PerSeptive Diagnostics), IL-4 (Laboserv, Staufenberg, Germany) and interferon gamma (IFN-γ) (Laboserv) concentrations were measured in the supernatant.
Statistical analysis
Nonparametric statistical analyses were performed throughout the study. The Mann-Whitney U-test was used for independent samples and correlations were made with the Spearman's rank correlation test. Values are expressed as mean±SEM. A p-value of less than 0.05 was considered significant. . 3) .
Results
CR1
Besides a decreased expression of CD59 on AMs from HIV-1 infected patients (p<0.05), no significant differences in the expression of any of the above-mentioned epitopes could be detected on AMs (table 1) (fig. 6 ).
Employing an assay with a lower limit of detection of 7.8 pg·mL -1 we failed to detect the Th2 cytokine IL-4 in supernatants of AC.
Pulmonary infection did not have any demonstrable effect on levels of expression of any of the investigated surface molecules in HIV-1 infected patients (data not shown).
Discussion
The broad spectrum of pulmonary diseases seen in HIV-1 infected patients is thought to be a consequence of a virus-induced local immunodeficiency, which is characterized by a severe depletion of CD4+ ALs [9] . Our study was therefore conducted to clarify whether, in HIV-1 infection, expression of complement regulatory and receptor proteins on ACs is altered and contributes to the decline of pulmonary cellular immunity. The main finding of the present study was a significant downregulation of the expression of the complement regulatory proteins CD46 and CD59 on CD4+ AL in HIV-1 infected individuals.
A decreased expression of complement regulatory proteins has been demonstrated on the surface of peripheral blood T-cells from HIV infected patients [8, 11] . In contrast to these reports we found no reduction of CD55 on ALs, which might be due to a low level of expression in HIV-1 negative controls. Unlike previous investigators [8] , we detected a reduced expression of complement regulatory proteins, primarily on CD4+ ALs with only a trend toward reduction in the CD4-subset (data not shown). These discrepancies may be attributable to the different investigational sites.
A dysregulation of the expression of complement controlling proteins is known to be of pathogenetic importance in other viral infections, such as measles, where a viral tropism for CD46 on lymphocytes might account for the observed lymphopenia [12] . In HIV-1 infection a loss of complement regulatory proteins is known to facilitate ACC of infected CD4+ T-cells [5] and might render them susceptible for apoptosis [13, 14], as recently described for blood polymorphonuclear leucocytes [15] .
The following mechanisms may contribute to the downregulation of membrane-bound complement regulatory proteins in HIV-1 infection.
Cytokine-mediated regulation
In human vascular endothelial cells the expression of CD46, CD55 and CD59 is regulated by cytokines [16] . An increased production of TNF-α and IL-1β by blood monocytes [17] and AMs [9, 18] in AIDS patients has been reported. However, we could not establish a correlation between CD46 and CD59 expressed on CD4+ ALs and TNF-α and IL-1β levels. This may be due to the influence of other cytokines, which are known to play a role in the pulmonary immune response to HIV-1 infection. T-cell derived IL-2, for example, has been shown to reconstitute expression of complement regulatory proteins on CD4+ T-cells from HIV-1 infected patients when cultured in vitro [19] , which might be one of the mechanisms that account for the rise in CD4+ T-cell counts in some patients treated with intermittent infusions of IL-2 [20] .
Virus-induced effect
In productively infected CD4+ ALs, HIV-1 itself might cause a reduced expression of complement regulatory proteins. This is due to an incorporation of CD55 and CD59 into newly produced virions protecting them from complement-mediated destruction [21] . However, presuming that the viral load in lung tissue parallels the plasma levels as has been shown for lymph nodes [22] , we were not able to establish a correlation between the available plasma HIV-1 ribonucleic acid (RNA) levels (n=13) and the antigen expression on CD4+ AL (data not shown).
Activation-induced effect
We found evidence to assume that immune activation is associated with decreased expression of complement regulatory proteins on the surface of CD4+ ALs. The increased expression of LFA-1 and ICAM-1 on CD4+ ALs might be of functional importance since cell adhesion and intercellular communication are essential mechanisms of cellular immunity.
Th1/Th2 shift
The expression of CD30 was inversely related to the decline of CD46 and CD59 expression. CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily [23] . CD30 is not exclusively [24] , but preferentially [10] , expressed on activated CD4+ Tcell clones that produce Th2 cytokines. This finding is supported by the negative correlation we found within the HIV-1 infected cohort between the expression of CD30 on CD4+ ALs and the concentrations of IFN-γ in supernatants of ACs. Unfortunately we were not able to detect IL-4 in supernatants of ACs. This finding is consistent with previous studies reporting high levels of IFN-γ and no detectable IL-4 in supernatants of ALs obtained from HIV-1 infected individuals [25] . A relative predominance of Th2 cells in HIV-1 infection as a consequence of apoptosis and anergy of Th1 cells has recently been postulated [26] .
In conclusion, our data indicate that the dysregulation of the expression of cell-bound components of the complement network on CD4+ alveolar lymphocytes from human immunodeficiency virus-1 infected individuals is related to an increased activation of the immune system and a shift in the type 1/type 2 T-helper cell profile. Future studies have to address the functional relevance of these findings for the CD4+ T-cell depletion taking place in the pulmonary compartment.
